![]() |
Name |
(2Z,6E)-Farnesyl acetate
|
Molecular Formula | C17H28O2 | |
IUPAC Name* |
[(2Z,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl] acetate
|
|
SMILES |
CC(=CCC/C(=C/CC/C(=C\COC(=O)C)/C)/C)C
|
|
InChI |
InChI=1S/C17H28O2/c1-14(2)8-6-9-15(3)10-7-11-16(4)12-13-19-17(5)18/h8,10,12H,6-7,9,11,13H2,1-5H3/b15-10+,16-12-
|
|
InChIKey |
ZGIGZINMAOQWLX-HDVIWIBHSA-N
|
|
Synonyms |
(2Z,6E)-Farnesyl acetate; (Z,E)-farnesyl acetate; (Z)-Farnesyl acetate; Farnesyl acetate, (2Z,6E)-; cis-2-trans-6-Farnesyl acetate; 24D243N5BV; 40266-29-3; FEMA No. 4213, (2Z,6E)-; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, 1-acetate, (2Z,6E)-; cis-trans-Farnesyl acetate; SCHEMBL806690; UNII-24D243N5BV; ZINC5829138; Q27253842; (2Z,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol acetate
|
|
CAS | 40266-29-3 | |
PubChem CID | 1551480 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 264.4 | ALogp: | 5.3 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 9 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 19 | QED Weighted: | 0.438 |
Caco-2 Permeability: | -4.607 | MDCK Permeability: | 0.00002690 |
Pgp-inhibitor: | 0.882 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.026 | 20% Bioavailability (F20%): | 0.99 |
30% Bioavailability (F30%): | 0.632 |
Blood-Brain-Barrier Penetration (BBB): | 0.78 | Plasma Protein Binding (PPB): | 97.89% |
Volume Distribution (VD): | 2.118 | Fu: | 2.79% |
CYP1A2-inhibitor: | 0.928 | CYP1A2-substrate: | 0.147 |
CYP2C19-inhibitor: | 0.442 | CYP2C19-substrate: | 0.48 |
CYP2C9-inhibitor: | 0.404 | CYP2C9-substrate: | 0.881 |
CYP2D6-inhibitor: | 0.615 | CYP2D6-substrate: | 0.336 |
CYP3A4-inhibitor: | 0.265 | CYP3A4-substrate: | 0.249 |
Clearance (CL): | 6.528 | Half-life (T1/2): | 0.801 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.72 |
Drug-inuced Liver Injury (DILI): | 0.04 | AMES Toxicity: | 0.002 |
Rat Oral Acute Toxicity: | 0.002 | Maximum Recommended Daily Dose: | 0.023 |
Skin Sensitization: | 0.956 | Carcinogencity: | 0.077 |
Eye Corrosion: | 0.279 | Eye Irritation: | 0.938 |
Respiratory Toxicity: | 0.015 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001466 | ![]() |
0.729 | D09XWD | ![]() |
0.589 | ||
ENC001465 | ![]() |
0.729 | D05XQE | ![]() |
0.542 | ||
ENC001462 | ![]() |
0.679 | D03VFL | ![]() |
0.433 | ||
ENC001096 | ![]() |
0.679 | D0M1PQ | ![]() |
0.242 | ||
ENC001467 | ![]() |
0.630 | D01ZUA | ![]() |
0.238 | ||
ENC002413 | ![]() |
0.621 | D0Q6DX | ![]() |
0.233 | ||
ENC001717 | ![]() |
0.621 | D0Q9HF | ![]() |
0.226 | ||
ENC001716 | ![]() |
0.574 | D06BLQ | ![]() |
0.222 | ||
ENC003133 | ![]() |
0.566 | D0Q7ZQ | ![]() |
0.212 | ||
ENC006119 | ![]() |
0.518 | D0X7XG | ![]() |
0.210 |